Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.

Saved in:

Bibliographic Details
Title:	Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
Authors:	Su JY; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China.; Tongde Hospital of Zhejiang Province Hangzhou 310012, Zhejiang, China., Huang T; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Zhang JL; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Lu JH; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Wang ML; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Yan J; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Lin RB; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China., Lin SY; Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou 310000, Zhejiang, China., Wang J; Hangzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University Hangzhou 310007, Zhejiang, China.
Source:	American journal of cancer research [Am J Cancer Res] 2024 Feb 15; Vol. 14 (2), pp. 407-428. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024).
Publication Type:	Journal Article; Review
Journal Info:	Publisher: e-Century Pub. Corp Country of Publication: United States NLM ID: 101549944 Publication Model: eCollection Cited Medium: Print ISSN: 2156-6976 (Print) Linking ISSN: 21566976 NLM ISO Abbreviation: Am J Cancer Res Subsets: PubMed not MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2156-6976